Health
Weight-loss experts predict 5 major treatment changes likely to emerge in 2026
NEWYou can now listen to Fox News articles!
Big moves are continuing in the weight loss landscape in the new year following breakthrough research of GLP-1 medications and other methods.
Weight-loss experts spoke with Fox News Digital about their predictions for the most major changes to come in 2026.
No. 1: Shift to whole-body treatment
Dr. Peter Balazs, a hormone and weight loss specialist in New York and New Jersey, shared that the most important shift is likely to label GLP-1 drugs as “multi-system metabolic modulators” rather than “simple weight loss drugs.”
MORE AMERICANS MAY BE CLASSIFIED AS OBESE UNDER NEW DEFINITION, STUDY SUGGESTS
“The treatment goal is no longer just BMI reduction, but total cardiometabolic risk mitigation, with effects now documented across the liver, heart, kidneys and vasculature,” he said.
“We are seeing a significant reduction in major adverse cardiovascular events … and progression of renal disease,” he went on.
The focus of GLP-1 drugs will widen beyond weight loss and diabetes, according to experts’ predictions. (iStock)
Philip Rabito, M.D., a specialist in endocrinology, weight loss and wellness in New York City, also shared that “exciting” advancements lie ahead for weight-loss drugs, including GLP-1s and GIPs.
OLDER AMERICANS ARE QUITTING GLP-1 WEIGHT-LOSS DRUGS FOR 4 KEY REASONS
“These next‑generation agents, along with novel combinations that include glucagon and amylin agonists, are demonstrating even more impressive weight‑loss outcomes than currently available therapies, with the potential for better tolerability and sustained results,” he told Fox News Digital.
“There is also tremendous optimism around new federal agreements with manufacturers that aim to make these medications more widely accessible and affordable for the broad population of patients who need them most.”
No. 2: More convenient dosing
The typical prescription for a GLP-1 medication is a weekly injection, but delivery and dosing may be changing to more convenient methods in 2026, according to Balazs.
OPRAH JOINS WAVE OF CELEBRITIES WHO REVEALED DRAMATIC WEIGHT LOSS IN 2025
A daily 25 mg pill version of Novo Nordisk’s Wegovy, a semaglutide designed to treat obesity, is now approved and available for chronic weight management, offering a non-injectable option for some patients.
A once-weekly oral GLP-1 is currently in phase 2 trials, as well as an implant that aims for three to six months of drug delivery, Balazs noted.
Incisionless weight-loss procedures will rise as a lower-risk option, according to experts. (iStock)
No. 3: Less invasive surgery
In addition to decreased risk during surgery for GLP-1 users, Balazs also predicted that metabolic surgery without incision will rise as a better option.
“Incisionless endoscopic procedures — like endoscopic sleeve gastroplasty (non-surgical weight-loss procedure that makes the stomach smaller from the inside) and duodenal mucosal resurfacing (non-surgical procedure that resets part of the small intestine to help the body better handle blood sugar) — [may become] more durable and widely available,” he said.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“These offer significant metabolic benefits with shorter recovery and lower risk than traditional surgery.”
Rabito agreed that “rapid progress” in minimally invasive weight‑loss procedures is “opening powerful new options for patients who are hesitant to pursue traditional bariatric surgery.”
Bariatric surgery remains the most effective weight loss method, one specialist says. (iStock)
This avenue offers “meaningful and durable weight reduction with less risk, shorter recovery times and no external incisions,” the expert added.
Dr. Muhammad Ghanem, bariatric surgeon at the Orlando Health Weight Loss & Bariatric Surgery Institute, reiterated that surgery remains “the most successful modality for the treatment of obesity … with the highest weight loss and most durable outcomes as of yet.”
No. 4: Younger GLP-1 users
As Novo Nordisk’s Wegovy has been indicated for adolescents over 12 years old as an obesity treatment, Balazs commented that pediatric use of weight-loss drugs is “now a clinical reality.”
He predicted that other alternatives are likely to be approved in 2026 for younger users.
No. 5: High-tech, personalized access
Amid the growth of artificial intelligence, Balazs predicted an expansion in the clinical implementation of AI-driven weight-loss methods.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
This could include categorizing obesity into sub-types like “hungry brain,” “emotional hunger” and “slow burn” to personalize how therapy is prescribed while moving away from “trial and error,” he said.
Ghanem agreed that there will likely be a “big focus” on individualized testing for causes of obesity in 2026, as it’s a disease that can have “different causes in different people,” thus requiring different treatments.
AI and other digital opportunities will drive more access for weight-loss patients, experts say. (iStock)
The doctor anticipates that more patients will seek combinations of comprehensive treatments and programs.
“Patients are more aware that now we have a few weapons in our arsenal to combat obesity, and [they] are seeking a multidisciplinary and holistic approach,” Ghanem said.
CLICK HERE FOR MORE HEALTH STORIES
Treatment options will also turn digital with the rise of prescription digital therapeutics (PDTs) for weight loss, Balazs predicted.
“These are software applications delivering cognitive behavioral therapy, personalized nutrition and metabolic coaching through algorithms, often integrated with continuous glucose monitors, and reimbursed as medical treatments,” he said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Ghanem added that body composition analyzers, like DEXA scans, will likely be more widely used as awareness grows about the limitations of BMI and weight in assessing obesity.
Health
New blood test detects 90% of aggressive prostate cancer cases, beating current screenings
NEWYou can now listen to Fox News articles!
A new test could make it easier to detect high-risk prostate cancer cases earlier.
The blood test, called Stockholm3, is showing promise in clinical trials, beating out the traditional, standard prostate-specific antigen (PSA) test.
In a new study published in the Annals of Internal Medicine, researchers from the Karolinska Institutet in Sweden studied the test’s efficacy in more than 12,000 men — mostly Swedish or European — aged 50 to 74.
NEW PROSTATE CANCER TEST PINPOINTS DISEASE BETTER THAN PSA OPTION, STUDY FINDS
All participants were tested with PSA and Stockholm3 and were followed for two years. During the follow-up period, 443 men were diagnosed with aggressive prostate cancer.
Stockholm3 detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests.
Stockholm3 detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests. (iStock)
Stockholm3 missed “significantly fewer” serious cancer cases than PSA. The number of men incorrectly classified as high-risk was similar across both tests, according to a press release.
Thorgerdur Palsdottir, a researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, wrote in a statement that one of the major challenges in prostate cancer is being able to identify the cases that are “truly dangerous.”
‘DILBERT’ CREATOR’S DESPERATE PLEA SHINES SPOTLIGHT ON ALTERNATIVE PROSTATE CANCER DRUG
“Our results show that Stockholm3 identifies significantly more aggressive cancer cases than PSA without increasing the number of unnecessary follow-ups,” she said.
“These results point toward a potential change in how prostate cancer screening can be conducted,” the researcher added. “A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures.”
“A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures,” a researcher commented. (iStock)
Study co-author Hari Vigneswaran, chief medical officer of Stockholm3-maker A3P Biomedical, commented on these “promising” findings in an interview with Fox News Digital.
PROSTATE CANCER SCREENING AFTER 70: EXPERTS QUESTION GUIDANCE AFTER BIDEN’S DIAGNOSIS
He confirmed that the PSA has been the standard for prostate cancer screening since the 1990s despite its “well-documented limitations.”
CLICK HERE FOR MORE HEALTH STORIES
“It leads to invasive and costly follow-up testing, contributes to over-diagnosis of non-aggressive cancers and, most importantly, it misses a substantial share of aggressive disease,” Vigneswaran said.
When aggressive prostate cancer is found while still confined in the prostate, the five-year survival is close to 100%. (iStock)
When aggressive prostate cancer is found while still confined in the prostate, the five-year survival rate is close to 100%, which highlights the importance of early detection, according to the doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Data from the National Cancer Institute’s SEER database show that metastatic prostate cancer has risen over the past decade, suggesting that “we have not improved early detection of the aggressive, curable disease that screening is meant to catch,” Vigneswaran said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“The goal of screening is to find the cancers that need treatment while they are still curable, without raising the number of men who screen positive but don’t have aggressive disease,” he said.
Stockholm3 could reduce the need for unnecessary MRIs and biopsies, according to the researcher. (Getty Images)
Stockholm3 could reduce the need for unnecessary MRIs and biopsies, according to the researcher.
The findings did have some limitations. Stockholm3 is an investigational device and is not available for sale in the U.S., Vigneswaran noted.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The test estimates a man’s risk of aggressive prostate cancer, but a biopsy remains the gold standard for confirming the disease.
The company plans to seek FDA approval to use the test for routine screening and will “generate the evidence needed to support that pathway, including U.S. data,” Vigneswaran said.
Health
This Protein Smoothie Trick Helps Women Over 40 Lose Twice as Much Fat
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Health
These leafy greens could help protect your lungs, study suggests
NEWYou can now listen to Fox News articles!
Scientists have linked eating leafy green vegetables such as spinach, kale and broccoli to better lung health.
There are two primary forms of vitamin K found in foods. The primary kind is vitamin K1, found mainly in vegetables, which plays a major role in the body’s blood-clotting process.
CLICK HERE FOR MORE LIFESTYLE STORIES
Vitamin K2 is found in fermented foods, certain dairy products, eggs and meats and helps regulate calcium in the body and supports bone health.
Researchers at Australia’s Edith Cowan University examined whether dietary intake of vitamins K1 and K2 was associated with chronic obstructive pulmonary disease (COPD), asthma and lung function.
Leafy green vegetables are high in vitamin K1, a nutrient that researchers have observed conributes to improved lung health. (iStock)
“Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, are among the most prevalent noncommunicable diseases worldwide and were the third leading cause of death in 2019, accounting for 4 million deaths and affecting 454.6 million individuals globally,” the scientists reported in the introduction to their study, published in The American Journal of Clinical Nutrition.
“Although asthma and COPD can be managed with available treatments, neither condition is curable, underscoring the need for effective prevention strategies,” they added.
The leading cause of COPD is smoking, the Mayo Clinic reported. Exposure to other irritants, such as dust, chemicals and pollution, can also cause it.
The researchers analyzed data from 179,062 participants over a 10-and-a-half-year period and concluded that, “Higher dietary vitamin K1 intake was associated with better lung function and a lower rate of COPD.”
Researchers found that people who increased their vitamin K1 intake were less likely to develop COPD. (iStock)
Participants who consumed the most vitamin K1 had a 16% lower likelihood of COPD, the researchers observed. The effects were more pronounced in smokers and participants with high-risk occupations.
Consumption of vitamin K2 did not result in lower COPD rates.
“No association was observed for vitamin K1 or vitamin K2 intakes and asthma,” the researchers also wrote.
CLICK HERE FOR MORE LIFESTYLE STORIES
Associate Professor Marc Sim, who was involved in the study, said that it’s likely Vitamin K activates a protein that may help keep lung tissue flexible and prevent damage.
Because the study was observational, it cannot prove that vitamin K1 directly reduces COPD risk, only that higher intake was associated with better lung health.
Researchers have associated higher consumption of leafy green vegetables with better lung function. (iStock)
Just one extra serving of leafy greens “is an achievable way to boost your vitamin K1 intake,” said Chengfeng Li, one of the study’s researchers.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Other foods rich in vitamin K1 include collard greens, Swiss chard, Brussels sprouts and turnip greens.
-
News22 minutes agoThree firefighters killed on Colorado-Utah border as wildfires intensify
-
Los Angeles, Ca2 hours ago6 members of suspected South American burglary crew arrested by Irvine police
-
Detroit, MI2 hours agoDetroit Tigers seek split in home series vs Houston Astros on Sunday
-
San Francisco, CA2 hours agoPeople’s Budget Coalition Claims Victory After San Francisco Budget Restores Most Proposed Service Cuts – Davis Vanguard
-
Dallas, TX2 hours agoDallas weather: June 28 morning forecast
-
Miami, FL2 hours agoWhere to watch Miami Marlins vs St. Louis Cardinals: TV channel, start time, streaming for June 28
-
Boston, MA2 hours agoPolice: Man killed in crash caused by wrong-way driver on I-93 in Boston – Boston News, Weather, Sports | WHDH 7News
-
Denver, CO3 hours ago
Even without extension talks, Nikola Jokic has reiterated his desire to stay long-term in Denver